Next, to validate if the combination of lapatinib and CQ on HER2/GSDMB positive tumors would be an effective therapeutic approach, we assayed its functional effect on tumor growth in vivo using two different preclinical models, zebrafish, and mice (Fig. 4). Here, ERBB2 is linked to neoplasm.